Recruiting
Phase 1
Phase 2

EC-104

Sponsor:

Eclipse Life Sciences, Inc.

Code:

NCT06536491

Conditions

Diabetic Macular Edema

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

EC-104 high dose

EC-104 low dose

Dexamethasone intravitreal implant

Study Details

Brief summary:

This is a prospective, randomized, subject- and evaluator-masked, Phase 2, multicenter study comparing the safety and efficacy of EC-104-6M high-dose (fluocinolone acetonide \[FA\] 0.14 mg) implant and EC-104-4M low-dose (FA 0.092 mg) implant to Ozurdex® (dexamethasone intravitreal (IVT) implant, 0.7 mg) in subjects with diabetic retinopathy (DR) and center-involving diabetic macular edema (DME), with prior suboptimal clinical response to IVT anti-VEGF therapy who have been previously treated with locally administered corticosteroids without a clinically significant rise in intraocular pressure (IOP).

Conditions

Diabetic Macular Edema

Study ID

NCT06536491

Start date

Aug 19, 2024

Status verified date

Jan, 2025

Completion date

Dec 31, 2025

Anticipated

Primary completion date

Dec 31, 2025

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Males or females who are at least 18 years of age at the time of informed consent
2. Willing and able to provide signed informed consent (participant or legally authorized representative) prior to any study-related procedures and to comply with all study visits and cooperate with all examinations
3. Diagnosis of diabetes mellitus (Type 1 or Type 2), with history of diabetic macular edema (DME) < = years duration prior to Screening Visit 1
4. Currently monitored hemoglobin A1c values ≤ 10.0 while under the care of a qualified medical provider for diabetes mellitus management, unless provider allows value variance

Inclusion criteria for the study eye (all of the below criteria must be met in the same eye):
5. Early Treatment Diabetic Retinopathy Study BCVA score ≤ 70 letters (Snellen equivalent 20/40 or worse) and ≥ 20 letters (Snellen equivalent 20/400) in at least 1 eye

Exclusion Criteria:

1. Previous or current diagnosis of any form of glaucoma (defined as cup-to-disc ratio > 0.7) or ocular hypertension (documented intraocular pressure (IOP) > 21 mm Hg without glaucomatous disc damage) requiring medical or surgical intervention
2. History of steroid-induced IOP elevation > 25 mm Hg
3. Presence of active proliferative diabetic retinopathy, defined as active neovascularization of disc (NVD), neovascularization elsewhere (NVE), neovascularization of iris (NVI), neovascularization of angle (NVA), or vitreous hemorrhage in the setting of active NVD or NVE

Study Design

Enrollment

75 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: EC-104 high dose

Intravitreal implant of fluocinolone acetonide

experimental: EC-104 low dose

Intravitreal implant of fluocinolone acetonide

active comparator: Dexamethasone intravitreal implant

Marketed product

Interventions

EC-104 high dose

Intravitreal injection

EC-104 low dose

Intravitreal injection

Dexamethasone intravitreal implant

Marketed product intravitreal injection

Primary outcome measure

  • Ocular and Systemic Safety [ Time Frame: Through Week 24 ]

Central Contacts and Locations

Central contacts

Locations

Retina Associates of Florida, LLC

Recruiting

Tampa, Florida, United States, 33609

More Information

Sponsor

Eclipse Life Sciences, Inc.

Last update posted

Jan 22, 2025

Last verified

Jan, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Eclipse Life Sciences, Inc. on 2025-01-22.